{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T21:05:19Z","timestamp":1765659919002,"version":"3.48.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF004"],"award-info":[{"award-number":["ZF004"]}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF004"],"award-info":[{"award-number":["ZF004"]}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF004"],"award-info":[{"award-number":["ZF004"]}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF004"],"award-info":[{"award-number":["ZF004"]}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF004"],"award-info":[{"award-number":["ZF004"]}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF004"],"award-info":[{"award-number":["ZF004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>T-cell immunotherapy is reshaping cancer care and offers a targeted strategy for pancreatic carcinoma (PC), yet a comprehensive map of its research trajectory is lacking. We aimed to chart the evolution of the field, identify leading contributors, and clarify the thematic shifts that are shaping clinical translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically analyzed articles and reviews indexed in the Science Citation Index Expanded of the Web of Science Core Collection from January 2000 to December 2024. Bibliographic metadata were aggregated for descriptive trend analyses and science-mapping of co-authorship, co-citation, and keyword co-occurrence networks. Temporal trend profiling was used to highlight emerging topics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Global output on T-cell immunotherapy for PC has expanded markedly over the past two decades but remains unevenly distributed across regions. The United States leads in academic influence and translational impact, with China closely following in publication volume and contributions from high-impact institutions. Research has converged at the interface of immunotherapy, tumor-microenvironment modulation, and cellular engineering. Dominant themes include engineered T-cell approaches, immune-checkpoint modulation, and strategies leveraging tumor-infiltrating lymphocytes. Emerging fronts encompass AI-enabled target\/drug discovery, biomarker-guided patient stratification, and individualized treatment designs. Persisting barriers include limited efficacy in the desmoplastic and immunosuppressive PC microenvironment, primary and acquired immune resistance, safety concerns, and regulatory and trial-design complexities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>T-cell immunotherapy for PC is a rapidly advancing, interdisciplinary domain led by the United States with rising contributions from China. Accelerating clinical translation will require: integrated T-cell engineering with microenvironment remodeling; rational combinations with checkpoint and stroma-targeted agents; robust predictive biomarkers with standardized endpoints; safety-engineering and risk-mitigation frameworks; and coordinated, multicenter collaboration. This bibliometric synthesis delineates the field\u2019s structure and priorities to improve outcomes for patients with PC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06356-x","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:00:40Z","timestamp":1762264840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century"],"prefix":"10.1007","volume":"151","author":[{"given":"Ziniu","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qipeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"6356_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-042617-053429","volume":"36","author":"A Alcover","year":"2018","unstructured":"Alcover A, Alarc\u00f3n B, Di Bartolo V (2018) Cell biology of T cell receptor expression and regulation. Annu Rev Immunol 36:103\u2013125","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"6356_CR2","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/ccr3.2412","volume":"7","author":"A Argentiero","year":"2019","unstructured":"Argentiero A, Calabrese A, Solimando AG, Notaristefano A, Panarelli MMG, Brunetti O (2019) Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: a case report and literature review. Clin Case Rep 7(10):1972\u20131976","journal-title":"Clin Case Rep"},{"issue":"5","key":"6356_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2217\/pme-2023-0083","volume":"20","author":"M Basiri","year":"2023","unstructured":"Basiri M (2023) Personalized medicine, the inevitable future of cancer immunotherapy. Personalized Med 20(5):413\u2013416","journal-title":"Personalized Med"},{"issue":"7","key":"6356_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S (2023) TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv 9(7):eadf3700","journal-title":"Sci Adv"},{"issue":"1","key":"6356_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, O\u2019Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM et al (2018) Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155(1):29\u201332","journal-title":"Gastroenterology"},{"key":"6356_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","volume":"24","author":"T Boon","year":"2006","unstructured":"Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175\u2013208","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"6356_CR7","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5342","volume":"60","author":"J Cao","year":"2022","unstructured":"Cao J, Chan WC, Chow MSS (2022) Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: current and future perspectives (review). Int J Oncol 60(5):52","journal-title":"Int J Oncol"},{"issue":"5","key":"6356_CR8","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2021.02.019","volume":"184","author":"Z Chen","year":"2021","unstructured":"Chen Z, Arai E, Khan O, Zhang Z, Ngiow SF, He Y, Huang H, Manne S, Cao Z, Baxter AE et al (2021) In vivo CD8(+) T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184(5):1262-1280.e1222","journal-title":"Cell"},{"issue":"1","key":"6356_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17(1):54","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6356_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81\u201394","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"6356_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomat\u00e0","year":"2023","unstructured":"Falcomat\u00e0 C, B\u00e4rthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D (2023) Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov 13(2):278\u2013297","journal-title":"Cancer Discov"},{"issue":"1","key":"6356_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C (2023) Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther 8(1):450","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"6356_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18(3):197\u2013218","journal-title":"Nat Rev Drug Discov"},{"key":"6356_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102227","volume":"101","author":"CL Gerard","year":"2021","unstructured":"Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O (2021) Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev 101:102227","journal-title":"Cancer Treat Rev"},{"issue":"46","key":"6356_CR15","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.3748\/wjg.v27.i46.7956","volume":"27","author":"MR Goulart","year":"2021","unstructured":"Goulart MR, Stasinos K, Fincham REA, Delvecchio FR, Kocher HM (2021) T cells in pancreatic cancer stroma. World J Gastroenterol 27(46):7956\u20137968","journal-title":"World J Gastroenterol"},{"issue":"6","key":"6356_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1056\/NEJMcibr2033544","volume":"384","author":"JM Goverman","year":"2021","unstructured":"Goverman JM (2021) Regulatory t cells in multiple sclerosis. N Engl J Med 384(6):578\u2013580","journal-title":"N Engl J Med"},{"issue":"22","key":"6356_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, Kang X, Olsen MN, Good Z, Dahiya S et al (2024) Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med 390(22):2047\u20132060","journal-title":"N Engl J Med"},{"issue":"4","key":"6356_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY (2020) Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38(4):473\u2013488","journal-title":"Cancer Cell"},{"issue":"1","key":"6356_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-24-0089","volume":"13","author":"Y Hou","year":"2025","unstructured":"Hou Y, Zak J, Shi Y, Pratumchai I, Dinner B, Wang W, Qin K, Weber EW, Teijaro JR, Wu P (2025) Transient EZH2 suppression by tazemetostat during in vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy. Cancer Immunol Res 13(1):47\u201365","journal-title":"Cancer Immunol Res"},{"issue":"7620","key":"6356_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH et al (2016) Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537(7620):417\u2013421","journal-title":"Nature"},{"issue":"1","key":"6356_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","volume":"43","author":"Y Isshiki","year":"2025","unstructured":"Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J et al (2025) Ezh2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell 43(1):49-68.e49","journal-title":"Cancer Cell"},{"issue":"5","key":"6356_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/87720","volume":"2","author":"SM Kaech","year":"2001","unstructured":"Kaech SM, Ahmed R (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in na\u00efve cells. Nat Immunol 2(5):415\u2013422","journal-title":"Nat Immunol"},{"issue":"2","key":"6356_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s43018-024-00891-1","volume":"6","author":"J Keyl","year":"2025","unstructured":"Keyl J, Keyl P, Montavon G, Hosch R, Brehmer A, Mochmann L, Jurmeister P, Dernbach G, Kim M, Koitka S et al (2025) Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence. Nat Cancer 6(2):307\u2013322","journal-title":"Nat Cancer"},{"issue":"25","key":"6356_CR24","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1056\/NEJMe1813684","volume":"379","author":"HL Kindler","year":"2018","unstructured":"Kindler HL (2018) A glimmer of hope for pancreatic cancer. N Engl J Med 379(25):2463\u20132464","journal-title":"N Engl J Med"},{"issue":"6","key":"6356_CR25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q et al (2015) Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162(6):1242\u20131256","journal-title":"Cell"},{"issue":"11","key":"6356_CR26","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.ymthe.2020.07.017","volume":"28","author":"AH Ko","year":"2020","unstructured":"Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L et al (2020) Dual targeting of Mesothelin and CD19 with chimeric antigen receptor-modified T cells in patients with metastatic Pancreatic cancer. Mol Ther 28(11):2367\u20132378","journal-title":"Mol Ther"},{"issue":"2","key":"6356_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H et al (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40(2):201-218.e209","journal-title":"Cancer Cell"},{"issue":"5","key":"6356_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick MB, Silva H, Scarf\u00f2 I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC et al (2022) Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40(5):494-508.e495","journal-title":"Cancer Cell"},{"issue":"4","key":"6356_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen J, Blank CU et al (2019) Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell 176(4):775-789.e718","journal-title":"Cell"},{"issue":"12","key":"6356_CR30","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.83495","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Li F, Ma Q, Du M, Wang H, Zhu Y, Deng L, Gao W, Wang C, Liu Y et al (2023) OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment. Theranostics 13(12):4016\u20134029","journal-title":"Theranostics"},{"issue":"1","key":"6356_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-bioeng-110222-111259","volume":"26","author":"C Loy","year":"2024","unstructured":"Loy C, Ahmann L, De Vlaminck I, Gu W (2024) Liquid biopsy based on cell-free DNA and RNA. Annu Rev Biomed Eng 26(1):169\u2013195","journal-title":"Annu Rev Biomed Eng"},{"issue":"15","key":"6356_CR32","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni F, Zhakyp A, Corsini M, Geels SN, Carrizosa E, Thelen M, Mani V, Pr\u00fc\u00dfmann JN, Warner RD, Ozga AJ et al (2021) Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184(15):3998-4015.e3919","journal-title":"Cell"},{"issue":"7","key":"6356_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, Bonastre J, Castro E, Dienstmann R, Kr\u00e4mer A et al (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group. Ann Oncol off J European Soc Med Oncol 35(7):588\u2013606","journal-title":"Ann Oncol off J European Soc Med Oncol"},{"issue":"5","key":"6356_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira G, Wu CJ (2023) Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer 23(5):295\u2013316","journal-title":"Nat Rev Cancer"},{"key":"6356_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-3-030-38862-1_6","volume":"180","author":"SI Pai","year":"2020","unstructured":"Pai SI, Cesano A, Marincola FM (2020) The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treat Res 180:173\u2013195","journal-title":"Cancer Treat Res"},{"issue":"8","key":"6356_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng K, Zhao X, Fu YX, Liang Y (2025) Eliciting antitumor immunity via therapeutic cancer vaccines. Cell Mol Immunol 22(8):840\u2013868","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"6356_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41568-024-00694-7","volume":"24","author":"R Perez-Lopez","year":"2024","unstructured":"Perez-Lopez R, Ghaffari Laleh N, Mahmood F, Kather JN (2024) A guide to artificial intelligence for cancer researchers. Nat Rev Cancer 24(6):427\u2013441","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"6356_CR38","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1021\/nn405520d","volume":"8","author":"K Perica","year":"2014","unstructured":"Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP (2014) Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano 8(3):2252\u20132260","journal-title":"ACS Nano"},{"issue":"4","key":"6356_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A (2022) CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol 22(4):209\u2013223","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"6356_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP, Tan M, Padmanabhan AA, Lemoine J et al (2025) EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell 43(3):537-551.e537","journal-title":"Cancer Cell"},{"issue":"4","key":"6356_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269\u2013281","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"6356_CR42","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M et al (2018) Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 175(4):998-1013.e1020","journal-title":"Cell"},{"issue":"3","key":"6356_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4236\/jct.2013.43096","volume":"4","author":"DE Sanford","year":"2013","unstructured":"Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG et al (2013) A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. J Cancer Ther 4(3):797\u2013803","journal-title":"J Cancer Ther"},{"issue":"6580","key":"6356_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Bueno R, Nguyen VQ, Blaeschke F, Ye CJ, Marson A (2022) CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375(6580):eabj4008","journal-title":"Science"},{"issue":"8056","key":"6356_CR45","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA et al (2025) RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639(8056):1042\u20131051","journal-title":"Nature"},{"issue":"2","key":"6356_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma P, Allison JP (2020) Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 20(2):75\u201376","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"6356_CR47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S et al (2019) Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50(1):195-211.e110","journal-title":"Immunity"},{"issue":"6","key":"6356_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1056\/NEJMc2208623","volume":"387","author":"D Simnica","year":"2022","unstructured":"Simnica D, Kobold S (2022) Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 387(6):573","journal-title":"N Engl J Med"},{"issue":"3","key":"6356_CR49","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6356_CR50","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN (2018) T cell dysfunction in cancer. Cancer Cell 33(4):547\u2013562","journal-title":"Cancer Cell"},{"issue":"5","key":"6356_CR51","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu V, Sotillo E, Bjelajac JR, Chen C, Malipatlolla M, Guerrero JA, Xu P, Quinn PJ, Fisher C, Klysz D et al (2024) A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187(5):1278-1295.e1220","journal-title":"Cell"},{"issue":"2","key":"6356_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","volume":"45","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, Danilo M, Alfei F, Hofmann M, Wieland D et al (2016) T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 45(2):415\u2013427","journal-title":"Immunity"},{"issue":"4","key":"6356_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN (2020) CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer 20(4):218\u2013232","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"6356_CR54","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, \u00c1lvarez-Errico D, Esteller M (2020) The contribution of epigenetics to cancer immunotherapy. Trends Immunol 41(8):676\u2013691","journal-title":"Trends Immunol"},{"issue":"11","key":"6356_CR55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668","journal-title":"Nat Rev Immunol"},{"issue":"7798","key":"6356_CR56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, Chiang EY, Iftikhar H, O\u2019Gorman WE, Au-Yeung A et al (2020a) Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579(7798):274\u2013278","journal-title":"Nature"},{"key":"6356_CR57","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","volume":"11","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, Xu D (2020b) Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol 11:1731","journal-title":"Front Immunol"},{"key":"6356_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.810774","volume":"12","author":"K Wu","year":"2022","unstructured":"Wu K, Liu Y, Liu L, Peng Y, Pang H, Sun X, Xia D (2022) Emerging trends and research foci in tumor microenvironment of pancreatic cancer: a bibliometric and visualized study. Front Oncol 12:810774","journal-title":"Front Oncol"},{"issue":"1","key":"6356_CR59","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M (2024) Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther 9(1):274","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"6356_CR60","first-page":"940","volume":"16","author":"C Xie","year":"2018","unstructured":"Xie C, Xu X, Wang X, Wei S, Shao L, Chen J, Cai J, Jia L (2018) Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E(2). Oncol Lett 16(1):940\u2013948","journal-title":"Oncol Lett"},{"key":"6356_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 13:927153","journal-title":"Front Immunol"},{"issue":"1","key":"6356_CR62","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z (2024) Regulatory t cells in immune checkpoint blockade antitumor therapy. Mol Cancer 23(1):251","journal-title":"Mol Cancer"},{"key":"6356_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658753","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, Wu X, Du F, Li M, Cho CH et al (2021) Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol 12:658753","journal-title":"Front Immunol"},{"issue":"6589","key":"6356_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5282","volume":"376","author":"X Zhao","year":"2022","unstructured":"Zhao X, Kolawole EM, Chan W, Feng Y, Yang X, Gee MH, Jude KM, Sibener LV, Fordyce PM, Germain RN et al (2022) Tuning T cell receptor sensitivity through catch bond engineering. Science 376(6589):eabl5282","journal-title":"Science"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06356-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T21:01:46Z","timestamp":1765659706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06356-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":64,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6356"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06356-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"315"}}